You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療(00853.HK):心脈醫療科技上半年淨利預增38.80%到44.68%
格隆匯 07-17 06:23

格隆匯 7 月 17日丨微創醫療(00853.HK)發佈公告,根據管理層目前所得的數據,預料上海微創心脈醫療科技股份有限公司於截至2020年6月30日止六個月錄得利潤增長。公司持有心脈醫療科技的股權46.34%,其業績與公司財務報表綜合入賬。心脈醫療科技的股份在科創板上市。

截至2020年6月30日止六個月,歸屬於心脈醫療科技所有者的淨利潤為人民幣1.18億元到1.23億元,與上年同期相比增加38.80%到44.68%。歸屬於心脈醫療科技所有者的扣除非經常性損益的淨利潤為人民幣1.08億元到1.13億元,與上年同期相比增加40.44%到46.94%。

利潤增長主要由於心脈醫療科技近年上市的主要新產品穩步推進招標入院進程,逐步貢獻心脈醫療科技的收入增量,銷售收入在報告期內保持良好增長態勢。此外,報告期內心脈醫療科技費用支出較收入的比例有所降低,且心脈醫療科技使用部分募集資金及自有資金進行現金管理獲得一定利息收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account